TRT and GLP-1 Therapy Together in Las Vegas
One coordinated protocol, one clinical team. Built around protecting the lean mass that makes weight loss hold.
GLP-1 medications drive rapid fat loss, but a meaningful share of the weight lost on these therapies is lean body mass rather than fat. That lean mass loss lowers resting metabolic rate, reduces physical strength, and sets up the metabolic conditions that make weight regain likely after treatment stops.
For men with clinically confirmed low testosterone, testosterone replacement therapy paired with resistance training and adequate protein is the established mechanism for shifting the composition of weight loss toward fat and away from muscle. That is the clinical reason these two therapies belong in one coordinated plan rather than two separate prescriptions. Body Balance Medical runs this combined protocol in Las Vegas with baseline labs, body composition tracking, and ongoing provider oversight under a single clinical team. If you are starting from the weight loss side, our medical weight loss program covers the GLP-1 side on its own.
Why Patients Run Both Therapies Through One Clinic
Running GLP-1 receptor agonists and testosterone therapy through separate providers means nobody owns the interaction between them. At Body Balance Medical, one clinical team manages both, adjusts dosing against the same lab panels, and tracks body composition against fat mass and lean mass targets rather than scale weight.
- One team reading both sets of labs. Hormone panels and metabolic markers are interpreted together. Testosterone dosing often needs adjustment after substantial weight loss, and that adjustment happens in the same visit where GLP-1 titration is reviewed.
- Body composition built into the protocol. InBody scanning at every checkpoint measures lean mass, fat mass, and segmental distribution, which moves the conversation off the scale.
- In-person medical supervision at 7975 W Sahara Ave #101, not a telehealth subscription or a mail-order prescription.
- LegitScript certification, an independent verification of licensure, advertising compliance, and pharmacy sourcing standards.
- Combined-protocol pricing. Patients running both therapies qualify for a standing discount on compounded tirzepatide through the Balance Rate, which exists for exactly this use case.
The Problem This Protocol Solves: GLP-1 Muscle Loss
GLP-1 medications reduce appetite, slow gastric emptying, and enhance insulin secretion, producing a sustained caloric deficit. That deficit is what drives weight loss. They also improve insulin sensitivity, preferentially reduce visceral fat, and lower several metabolic syndrome risk factors.
The complication is that any large caloric deficit triggers predictable physiology. Reduced intake lowers insulin and IGF-1, which dampens the PI3K/Akt/mTOR signaling responsible for muscle protein synthesis. At the same time catabolic signaling rises: FoxO transcription factors activate muscle atrophy genes, cortisol increases, and autophagy accelerates. Muscle loss on these medications happens because of the deficit, not because the drugs target muscle tissue.
The clinical trials quantify it. In SURMOUNT-1, pooled tirzepatide subgroups lost roughly 10.9% of lean mass across 72 weeks, with lean soft tissue accounting for about a quarter of total weight lost. Figures for semaglutide run higher in some analyses, in the range of 30% to 40% of total weight lost at higher-potency dosing. For someone losing 20 kg, several of those kilograms can be lean mass when no protective measures are in place.
Losing muscle lowers resting metabolic rate, which narrows the gap between intake and expenditure. When a patient stops GLP-1 therapy, that lower metabolic rate is what makes regain more likely. This is the mechanism behind the pattern described on our weight gain and metabolism page.
An honest nuance. "Lean body mass" on DXA or bioimpedance includes organs, connective tissue, and body water, not only skeletal muscle. Some of the decline reflects healthy change, such as reduced liver fat or decreased organ mass in people carrying excess weight. Functional measures like grip strength and gait speed do not always fall in proportion to lean mass on a scan, particularly in patients eating adequately and training. The concern is real, but it is not as simple as the headlines suggest.
Where it does matter most is in older adults, patients starting with low baseline muscle mass, and anyone whose intake drops far enough that protein becomes an afterthought.
Protein intake becomes harder and more important at the same time, which is the core problem GLP-1 appetite suppression creates.
How Testosterone Optimization Changes the Equation
Testosterone influences protein synthesis through a specific pathway. Binding the androgen receptor in muscle cells upregulates IGF-1 transcription, activating the PI3K, Akt, and mTORC1 cascade that directly increases muscle protein synthesis. It simultaneously suppresses FoxO transcription factors, reducing the ubiquitin ligases that drive muscle catabolism, suppresses myostatin signaling, and supports satellite cell activation.
In human trials this translates into measurable preservation during caloric restriction. In a randomized controlled trial at Monash University, men with obesity and low testosterone on a weight loss program plus testosterone replacement therapy lost more visceral fat and retained more appendicular lean mass than placebo, a difference of roughly 3 to 4 kg. In a separate 56-week trial, men on testosterone plus a weight loss program lost more fat while preserving lean mass, and those differences largely disappeared after testosterone was stopped at 82 weeks. The benefit is tied to ongoing therapy.
Muscle is not the only tissue at risk during rapid weight loss. Bone density falls under the same conditions, and testosterone is protective there too. Our guide to hormone therapy and bone density covers the skeletal side of this for both men and women.
Resistance training is the other half. Mechanical loading activates mTORC1 in muscle fibers, and adequate androgen receptor signaling amplifies that response. Without adequate testosterone, the same training stimulus produces a smaller anabolic effect.
What the evidence does not yet show. No randomized controlled trial has directly evaluated GLP-1 therapy plus testosterone replacement plus resistance training for lean mass outcomes. The protocol is built on established individual levers, each with supporting evidence, rather than on one definitive trial of the combination. We would rather say that plainly than imply more certainty than exists. For further reading, see can you take TRT and tirzepatide together.
One distinction matters more than any other on this page. Testosterone replacement therapy is prescribed for diagnosed hypogonadism, not for weight loss, and it is not FDA-approved as a weight loss intervention. The Endocrine Society criteria require at least two morning measurements of total or free testosterone below the reference range, together with clinical symptoms such as reduced sexual function, fatigue, or loss of muscle mass, before starting treatment. Our page on TRT candidacy walks through the full diagnostic criteria.
Resistance training is the single strongest non-pharmacologic lever for protecting lean mass in a deficit.
Does Weight Loss Itself Raise Testosterone?
In many men, low testosterone is a consequence of excess abdominal fat rather than primary gonadal failure. Fat tissue contains aromatase, which converts testosterone to estradiol. In obesity, high aromatase activity, low sex hormone binding globulin, insulin resistance, and chronic inflammation together suppress the hypothalamic-pituitary-gonadal axis. The literature calls this functional or metabolic hypogonadism.
Weight loss can reverse part of it. A meta-analysis of 44 studies covering roughly 1,774 participants found that weight loss through a low-calorie diet raised total testosterone by an average of 2.5 nmol/L, while bariatric surgery raised it by about 7.2 nmol/L. Free testosterone rose in both groups.
The clinical implication is direct. Some patients need only GLP-1 therapy, because significant weight reduction restores healthy testosterone on its own. Others have deficiency that persists after weight loss, or that preceded the weight gain entirely. When weight loss is modest, in the range of 4% to 8% of body weight, testosterone gains are often small or not statistically significant. Age and baseline metabolic health shift the response further.
The baseline lab panel is what tells us which situation applies, and it is the reason the protocol starts with labs rather than a prescription.
How the Combined Protocol Actually Runs
The protocol starts with labs, not medication. Panels include total and free testosterone, sex hormone binding globulin, LH, FSH, and metabolic markers including fasting glucose, insulin, a lipid panel, and HbA1c. Inflammatory markers and IGF-1 are added when clinical presentation warrants. Baseline body composition is measured to establish lean mass, fat mass, and segmental distribution before anything begins.
Compounded semaglutide or compounded tirzepatide starts at the lowest effective dose and titrates upward based on tolerability and response, with scheduled check-ins for nausea and gastrointestinal symptoms. Which of the two fits you is a clinical decision made at this stage, and our tirzepatide versus semaglutide comparison covers how they differ. Protein targets of roughly 1.2 to 2.0 grams per kilogram of lean body weight per day, spread across meals with leucine-rich sources, are prescribed from day one rather than added later once muscle loss shows up on a scan.
If baseline labs confirm low testosterone on at least two morning draws alongside relevant symptoms, testosterone replacement begins. Delivery method, whether injection, pellet, or topical, is selected on clinical factors and patient preference. Dosing targets restoration of physiologic levels, not supraphysiologic enhancement. Patients whose testosterone sits in the normal range do not start TRT.
Body composition checkpoints run every 3 to 6 months, tracking lean mass and fat mass independently. Follow-up labs covering testosterone, hematocrit, PSA, and metabolic parameters run on the same cadence, since testosterone therapy affects red blood cell production. Testosterone dosing frequently needs adjustment after significant weight loss, because the hormonal picture shifts as fat mass declines. GLP-1 dosing is adjusted against weight trajectory, tolerability, and glycemic response.
Measuring What Matters: Beyond the Scale
Scale weight is the wrong metric when lean mass is the variable you are protecting. A patient who loses 15 kg with 6 of those from lean mass has a different metabolic and functional outcome than one who loses the same 15 kg with only 2 from lean mass. The scale reads identically.
Body composition analysis at each checkpoint measures segmental lean mass, fat mass, body water distribution, and visceral fat area, which is what distinguishes fat loss from muscle loss. Tracking that ratio over time is what shows whether the protein targets, the training, and the hormone optimization are actually producing the intended shift.
Functional measures matter alongside the scan. Grip strength, physical performance, and exercise capacity reflect whether changes on imaging translate into real-world consequences. Some patients lose lean mass on a scan while maintaining or improving strength through neuromuscular adaptation. The goal is not zero lean mass loss, which is not achievable under any substantial deficit. The goal is minimizing it.
Who This Protocol Is Not For
- Men planning conception. Exogenous testosterone suppresses natural production and sperm production. Men who want to preserve fertility should discuss alternatives such as Gonadorelin with their provider before starting TRT.
- Anyone with GLP-1 contraindications. Personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, are absolute contraindications per prescribing information.
- Anyone with TRT contraindications. Uncontrolled polycythemia, untreated obstructive sleep apnea, or active prostate malignancy require individual assessment before testosterone is considered.
- Men whose testosterone is already normal. TRT is not a weight loss intervention. Prescribing it to men with normal levels exposes them to polycythemia, fertility suppression, and hormonal disruption without the lean mass benefit seen in hypogonadal men.
- Patients who need only one therapy. Some men's hormone levels recover with weight loss alone. Others need hormone optimization and not GLP-1 therapy. There are no known drug interactions between the two, but the absence of an interaction is not a reason to prescribe both.
What the Combined Protocol Costs in Las Vegas
Each component is priced all-inclusive, covering medication, provider visits, and titration management.
Patients combining hormone optimization with weight loss therapy receive a standing discount on compounded tirzepatide through the Balance Rate membership. There is no separate assessment fee for the initial consultation. Lab work is ordered at baseline and at regular intervals, and lab costs depend on your insurance or preferred draw site.
Compounded medications are not covered by insurance, and TRT coverage varies by plan but is frequently excluded for compounded formulations. All pricing above is cash pay. The wider hormone program, including how testing and delivery methods work, is covered on the hormone optimization page linked in the breadcrumb above.
Areas We Serve
Body Balance Medical is at 7975 W Sahara Ave #101 in Summerlin. All consultations and InBody scans are conducted in person at the clinic.
Combined Therapy: Common Questions
Combined protocols at Body Balance Medical are built from labs and clinical history rather than a flat protocol. Your provider reviews your hormone panel, metabolic markers, and baseline body composition before any medication is prescribed.
Start With Your Lab Panel
The protocol begins with a hormone and metabolic panel, because the treatment decision depends on what the labs show. Whether that points to GLP-1 therapy alone, testosterone alone, or both, the data comes first.
Body Balance Medical · 7975 W Sahara Ave #101, Las Vegas, NV 89117
(702) 417-1261 · LegitScript Certified
This page is general educational information. It does not diagnose any condition, does not constitute medical advice, and does not establish a provider-patient relationship. Testosterone replacement therapy is prescribed for diagnosed hypogonadism confirmed on laboratory testing, is not approved as a weight loss treatment, and carries risks including effects on red blood cell production and fertility. GLP-1 therapy carries labeled warnings and contraindications that must be reviewed with a licensed provider. Compounded medications are not approved by the U.S. Food and Drug Administration and are prescribed only after individual clinical evaluation. Clinical figures cited reflect published trial populations and not Body Balance Medical patient outcomes. Individual results vary and are not guaranteed. If you are experiencing a medical emergency, call 911.